Stealth BioTherapeutics Corp MITO
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 23.54M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -6.40
- Beta
- 1.46
- Short ratio
- 1.77
- Inst. own
- 7.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 17, 2022
- 50-d avg
- 0.315554
- 200-d avg
- 0.368184
- 1y target
- 1.77
News
5 months ago prnewswire.com
FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions
Highlights FGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO ® Material Solutions, Inc. Strategic acquisition…
1 year ago prnewswire.com
Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
NEEDHAM, Mass. , Sept. 19, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and…
1 year ago prnewswire.com
STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
NEEDHAM, Mass. , Aug. 18, 2025 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for…
1 year ago reuters.com
US FDA asks Stealth BioTherapeutics to resubmit application for rare genetic condition therapy
The U.S. Food and Drug Administration has asked for a resubmission of Stealth BioTherapeutics' marketing application for its experimental therapy targeting a rare genetic condition, Barth syndrome,…
1 year ago reuters.com
FDA delays decision on Stealth BioTherapeutics' rare genetic disorder drug
The U.S. Food and Drug Administration has delayed its decision on marketing approval for Stealth BioTherapeutics' treatment for a rare genetic condition that typically affects boys, the drug…
1 year ago prnewswire.com
Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome
– New PDUFA Action Date of April 29, 2025, Allows FDA Additional Time to Complete Review – – Follows Positive FDA Advisory Committee Meeting Vote Concluding that Elamipretide is Effective for the…
2 years ago prnewswire.com
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
Barth Syndrome is an Ultra-rare, Progressive, Life-Shortening, Cardioskeletal Disease that Affects Approximately 150 Individuals in the United States If Approved, Elamipretide Would Become the First…
2 years ago prnewswire.com
Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference
NEEDHAM, Mass. , May 6, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and…
2 years ago prnewswire.com
STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
Barth Syndrome is an Ultra-rare, Progressive, Life-Shortening, Cardioskeletal Disease that Affects Approximately 150 Individuals in the United States If Approved, Elamipretide Would Become the First…
2 years ago prnewswire.com
Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series
NEEDHAM, Mass. , Dec. 4, 2023 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development, and…
-
4 years ago benzinga.com
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
4 years ago pennystocks.com
Good Penny Stocks to Buy Today? 3 to Watch Right Now
Here are three penny stocks to watch right now The post Good Penny Stocks to Buy Today? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 years ago benzinga.com
Why Stealth BioTherapeutics Shares Are Surging Today?
Stealth BioTherapeutics Corp (NASDAQ: MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a…
-
4 years ago benzinga.com
77 Biggest Movers From Yesterday
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows.
4 years ago pennystocks.com
What to Know About Buying Penny Stocks on May 10th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information |…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 351 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
4 years ago benzinga.com
Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study
Stealth BioTherapeutics Corp (NASDAQ: MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 431 companies hit new 52-week lows.
-
4 years ago benzinga.com
32 Stocks Moving in Wednesday's Pre-Market Session
Gainers Zentek Ltd. (NASDAQ: ZTEK) rose 180.5% to $7.63 in pre-market trading after declining around 5% on Tuesday.
4 years ago prnewswire.com
Stealth BioTherapeutics to Present at Upcoming March Investor Conferences
BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
4 years ago prnewswire.com
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
4 years ago prnewswire.com
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel…
4 years ago seekingalpha.com
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
-
4 years ago benzinga.com
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.
5 years ago benzinga.com
Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
Stealth BioTherapeutics Corp (NASDAQ: MITO) has received a Refusal to File letter from the FDA regarding its marketing application for elamipretide, a mitochondria-targeted therapy for Barth…
5 years ago prnewswire.com
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
BOSTON, Oct. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies…
-
5 years ago benzinga.com
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
-
5 years ago benzinga.com
Earnings Scheduled For May 18, 2021
Companies Reporting Before The Bell • Agrify (NASDAQ:AGFY) is expected to report quarterly loss at $0.31 per share on revenue of $5.80 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 62 stocks made new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For November 5, 2020
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX:BRG) is expected to report quarterly loss at $0.64 per share on revenue of $52.59 million.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Friday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Thursday